story of the week
Overall Survival Outcomes Following Adjuvant Olaparib Therapy in Patients With Germline Pathogenic Variants in BRCA1/2 and High-Risk Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer
Ann. Oncol 2022 Oct 10;[EPub Ahead of Print], CE Geyer, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, P Rastogi, K Cui, A Arahmani, G Aktan, AC Armstrong, M Arnedos, J Balmaña, J Bergh, J Bliss, S Delaloge, SM Domchek, A Eisen, F Elsafy, LE Fein, A Fielding, JM Ford, S Friedman, KA Gelmon, L Gianni, M Gnant, SJ Hollingsworth, SA Im, A Jager, ÓÞ Jóhannsson, SR Lakhani, W Janni, B Linderholm, TW Liu, N Loman, L Korde, S Loibl, PC Lucas, F Marmé, E Martinez de Dueñas, R McConnell, KA Phillips, M Piccart, G Rossi, R Schmutzler, E Senkus, Z Shao, P Sharma, CF Singer, T Španić, E Stickeler, M Toi, TA Traina, G Viale, G Zoppoli, YH Park, R Yerushalmi, H Yang, D Pang, KH Jung, A Mailliez, Z Fan, I Tennevet, J Zhang, T Nagy, GS Sonke, Q Sun, M Parton, MA Colleoni, M Schmidt, AM Brufsky, W Razaq, B Kaufman, D Cameron, C Campbell, ANJ TuttFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.